Cargando…
Clinical heterogeneity under induction with different dosages of cytarabine in core binding factor acute myeloid leukaemia
Repeated cycles of post-remission high-dose cytarabine (Ara-C) have been suggested to improve survival in core binding factor (CBF) acute myeloid leukaemia (AML). High-dose Ara-C used for induction regimens has also been reported to be associated with increased treatment-related mortality (TRM). Few...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971028/ https://www.ncbi.nlm.nih.gov/pubmed/31959790 http://dx.doi.org/10.1038/s41598-020-57414-y |